Latest news with #VentureCapital
Yahoo
3 days ago
- Business
- Yahoo
Israeli Startup Hub Under Missile Fire
Tel Aviv, one of the top global startup hubs, has been a regular target of Iranian missiles. Israeli entrepreneurs and venture investors say the heavy fire has made business travel impossible and affected productivity for some employees.
TechCrunch
3 days ago
- Business
- TechCrunch
In just 3 months, Ramp's valuation jumped to $16B, up from $13B
In Brief Spend management startup Ramp announced on Tuesday that it raised a $200 million Series E led by its largest investor, Founders Fund, at a post money $16 billion valuation. This is a jaw-dropping $3 billion increase over the $13 billion valuation Ramp announced just a few months ago in March from a $150 million secondary share sale. It's current valuation is also more than double the $7.65 billion Ramp hit a little over a year ago when it raised $150 million at a $7.65 billion post money. CEO Eric Glyman is remaining mum about revenue figures, although in March he said revenue had experienced 'incredible growth' over the previous figures it released. In the summer of 2023, he said Ramp had passed $300 million in annualized revenue. Other VCs, largely existing investors, who participated in the Series E round include Thrive Capital, D1 Capital Partners, General Catalyst, GIC, ICONIQ Growth, Khosla Ventures, Sands Capital, 8VC, Lux Capital, Stripes, 137 Ventures, Avenir Growth, and Definition Capital.
TechCrunch
3 days ago
- Business
- TechCrunch
In just 3 months, Ramp's valuation jumped to $16B from $13B
In Brief Spend management startup Ramp announced on Tuesday that it raised a $200 million Series E led by its largest investor, Founders Fund, at a post money $16 billion valuation. This is a jaw-dropping $3 billion increase over the $13 billion valuation Ramp announced just a few months ago in March from a $150 million secondary share sale. It's current valuation is also more than double the $7.65 billion Ramp hit a little over a year ago when it raised $150 million at a $7.65 billion post money. CEO Eric Glyman is remaining mum about revenue figures, although in March he said revenue had experienced 'incredible growth' over the previous figures it released. In the summer of 2023, he said Ramp had passed $300 million in annualized revenue. Other VCs, largely existing investors, who participated in the Series E round include Thrive Capital, D1 Capital Partners, General Catalyst, GIC, ICONIQ Growth, Khosla Ventures, Sands Capital, 8VC, Lux Capital, Stripes, 137 Ventures, Avenir Growth, and Definition Capital.
Indianapolis Star
13-06-2025
- Business
- Indianapolis Star
NeuroEM Therapeutics(R) Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer's Treatment
TAMPA, FL / ACCESS Newswire NeuroEM Therapeutics ®, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer's disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with The Series A round supports continued progress toward commercialization of NeuroEM's Transcranial Electromagnetic Treatment (TEMT-RF) to prevent and treat cognitive decline caused by aging or Alzheimer's and other neurodegenerative diseases. 'BlueLake's support demonstrates the importance of maintaining our momentum in the execution of key clinical, regulatory, and commercial milestones on our journey toward a safe, effective, drug-free treatment for Alzheimer's dementia and other neurodegenerative diseases,' says Chuck Papageorgiou, CEO of NeuroEM Therapeutics. 'It fuels the tireless efforts of our researchers, clinicians, engineers, and the entire NeuroEM team to restore the hope and dignity Alzheimer's disease has already stolen from millions and to one day prevent millions more from facing this devastating diagnosis.' The equity round is led by BlueLake Partner Jamie Rutledge, who also joins the NeuroEM Board of Directors. Rutledge focuses on early-stage investments in breakthrough technologies at BlueLake and is a seasoned technology investor and executive with deep expertise in strategic investment and innovation across the medical technology and consumer electronics sectors. He brings over 25 years of experience to NeuroEM, including senior leadership roles at Dyson and Lenovo. He previously led Lenovo's Strategic Venture Capital and Open Innovation initiatives and directed technology scouting and strategic investments at Dyson. 'NeuroEM's pioneering, non-invasive approach to treating and preventing Alzheimer's represents exactly the kind of patented, deep tech innovation we champion at BlueLake – transformative, defensible, and grounded in scientific rigor. This approach to drug-free treatment and prevention of Alzheimer's holds tremendous promise in tackling a disease that has eluded effective solutions for decades,' said Rutledge. 'We're proud to support the advancement of this groundbreaking technology, and I'm personally honored to help guide NeuroEM as it brings innovative, non-invasive therapies to the forefront of neurodegenerative care.' Adds Papageorgiou, 'Jamie's background in radio frequency systems, embedded devices, and product development aligns closely with our core technology, and his strategic insight will be a valuable asset as NeuroEM moves toward commercialization and broader market engagement.' NeuroEM Therapeutics, a member of StartUp Health's Alzheimer's Moonshot Community ™, is committed to developing, clinically testing, and marketing its multi-patented TEMT-RF technologies that target and reduce cognitive decline and restore immune balance in the brain and blood while boosting energy production in brain cells – critical elements for optimal cognitive function. Early studies have demonstrated that, as an Alzheimer's treatment, TEMT-RF is safe, enhances cognitive function, and may potentially modify the disease itself. The company's first commercial product, a lightweight cap designed for at-home use, is currently under development and has shown extraordinary promise in preclinical and clinical studies. Worn for an hour twice daily, the device uses short pulses of energy in specific ultra-high frequencies to deliver a transcranial electromagnetic treatment that improves key physical factors in the brain at the root of cognitive decline. BlueLake Ventures invests in applied deep tech for the future of work and health, technology defined by significant barriers to entry, such as strong patent protection or specialized domain expertise. Its team consists of experienced operators who have built and scaled startup companies, held executive positions in multi-national corporations, built partnerships between startups and corporations, and deployed strategic venture capital in technology-driven businesses. By leveraging its expertise, resources, and networks, BlueLake aims to accelerate the growth of deep tech innovations that empower both businesses and consumers. About NeuroEM Therapeutics ® NeuroEM Therapeutics is leading the way in the development and clinical testing of bioengineered technology to reverse the cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF), the company received the first Breakthrough Device status from the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease. NeuroEM's continued dedication to cutting-edge research is bringing to market a first-in-class wearable device designed for in-home use to extend healthy longevity using patented Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technology. To learn more, visit Media Contact: Liz Goar NPC Creative Services liz@ SOURCE: NeuroEM Therapeutics View the original press release on ACCESS Newswire
Zawya
12-06-2025
- Business
- Zawya
Israeli data security firm Cyera raises $540mln, value doubles to $6bln
JERUSALEM: Israeli data security startup Cyera said on Wednesday it raised $540 million in a late-stage private funding round that doubled its valuation to $6 billion over the past seven months. Cyera, whose platform is powered by AI, said it would use the funds to grow and scale its data security platform and capabilities. As enterprises rapidly embrace generative AI, copilots, and foundation models, securing the data that powers those systems has become a top priority, it added. "Across the board, we're hearing the need for enterprises to push hard on AI, yet they must move fast without compromising security and control," said co-founder and CEO Yotam Segev. "Cyera's focus on data security is the most critical capability the enterprise needs to adopt AI responsibly." The round was led by Georgian, Greenoaks, and Lightspeed Venture Partners, alongside existing investors Accel, Coatue, Cyberstarts, Redpoint, Sapphire, Sequoia Capital and Spark, the company said. In November, Cyera - founded in 2021 - raised $300 million for a total valuation of $3 billion. Cyera said that over the past 18 months, it posted 353% growth in Fortune 500 companies, expanded to 10 countries and more than doubled its size to nearly 800 employees globally. In that time it has raised $1.3 billion and its valuation has jumped 12 times.
